Epilepsy commonly presents in childhood as part of a syndrome, and some such children may reach adult services without an underlying syndromic diagnosis. For adult neurologists taking over their care, it is often unclear how hard to search for an underlying diagnosis. The diagnostic yield may be small and such a diagnosis may not change management. Young adults with learning difficulties are also challenging to investigate, as they may not tolerate standard epilepsy tests. We present such a case in which simple tests identified a unifying diagnosis. With the new diagnosis came a new treatment that had a significant impact on seizures and quality of life.
HISTORY
This 26-year-old male was born following a normal pregnancy and delivery, but had evidence of neurodevelopmental delay by the age of 6 months. He never acquired language, and sitting and walking were delayed. He showed autistic spectrum behaviour. Seizures began at the age of 7 years, including drop attacks, convulsions and milder atypical absence episodes, and were relentless despite treatment with various antiepileptic drugs.
He was investigated at a tertiary centre for paediatric epilepsy. Brain magnetic resonance imaging was normal. Electroencephalogram (EEG) captured several clinical events of a deep sigh followed by head dropping. Figure 1 shows his childhood EEG. The interictal EEG background was slow for his age at the time of the study (13 years), dominated by moderate amplitude theta and more irregular delta, and showed no definite posterior dominant rhythm. Eleven seizures were captured during the 15 min recording. He would breathe heavily for 4-5 s before stiffening with a vocalisation. His head would drop slightly with eyes closed and ventilation slowed significantly. He made a rapid return to baseline behaviour. Electrographically, there was an increase in slow activity after clinical onset, before high-amplitude 1-2 Hz sharp-slow wave complexes (right more sharp than left) dominated the EEG. There were sharp transients over the right centrotemporal region following clinical offset before background activity returned. The EEG was not felt to be diagnostic of a particular syndrome.
An older sibling also had epilepsy and learning difficulties which raised the suspicion of a genetic cause. A karyotype was normal and mono-gene testing for Angelman syndrome was negative.
Aged 14 years he underwent corpus callosotomy as a palliative treatment for his drop attacks. He was seizure free for 2 weeks postoperatively before seizures returned to baseline frequency and severity.
At transfer to adult services, aged 18 years, he was independently mobile, but dependent on others for care, unable to speak and doubly incontinent. He was experiencing very frequent atypical absence seizures (sometimes more than 1000 in a day) and around two convulsions per year. Seizures were often triggered by hyperventilation in stressful situations such as medical appointments. He was taking sodium valproate, and the following drugs had been ineffective: phenytoin, lamotrigine, levetiracetam and carbamazepine.
On examination, he was not dysmorphic. He was slim but strong, with normal muscle bulk. He had a relatively normal gait, without any obvious lateralising signs, but some flexed posturing of the hands. He could walk and run unassisted. He could track and interact with objects and recognise carers and relatives. There was frequent hand clasping and he was restless and hyperactive. He was reluctant to stay put for more than a few minutes, and did not cooperate with a formal neurological examination. He had no speech.
Array comparative genomic hybridisation (array-CGH) was normal. He was thought unlikely to tolerate further imaging or EEG without sedation; therefore, these were not pursued.
Following routine blood tests some years later, his serum creatinine was noted to be low at 20 mmol/L (normal range 66-112). This raised the suspicion of a creatine biosynthesis disorder as a cause for his syndrome. Table 1 shows the results of further biochemical investigations.
Genetic testing of the CCDS gene confirmed the diagnosis of guanidinoacetate methyltransferase (GAMT) deficiency, with a homozygous c.327G>A mutation, the most commonly described pathogenic mutation. His older sibling had the same homozygous mutation.
Guanidinoacetate methyltransferase (GAMT) deficiency GAMT deficiency was first described in 1994 1 ; a recent review identified 48 people with reported diagnosis and outcomes. 2 A recent pilot study using genetic screening in 500 newborns estimated its incidence at 1:250 000. 3 Lack of awareness and relatively nonspecific features mean that the diagnosis is often made late or missed, even in specialist centres. The condition is inherited in an autosomal recessive fashion.
Typical clinical features include developmental delay from infancy, learning difficulties, epilepsy, autism and behavioural problems. There is sometimes a movement disorder and self-mutilating behaviour, although not in our case. Speech may be more affected than other cognitive domains, with relative sparing of motor function. 2 GAMT converts guanidinoacetate into creatine (see figure 2A) . 4 GAMT deficiency causes raised plasma and urine guanidinoacetate, and low creatine and creatinine (figure 2B). Low plasma creatinine is a non-specific finding and needs to be viewed in the context of overall muscle mass, but in the correct clinical setting it suggests the need for more specialised tests.
Biochemical tests of the blood and urine for guanidinoacetate, creatine and creatinine can be diagnostic, with our case's results typical. Standard MR scan of the brain may show bilateral hyperintensities in the globus pallidus, but may be normal. MR spectroscopy shows depleted or absent creatine in the brain and is diagnostic of the condition, but in our case it would have required a general anaesthetic and therefore was not attempted. MR spectroscopy can be repeated following treatment to demonstrate improvement. Genetic testing from blood or saliva can identify the causative mutation.
The enzyme deficiency leads to cerebral creatine deficiency and raised guanidinoacetate which both appear to contribute to the clinical syndrome. 5 Creatine and creatine kinase are vital for energy production in all tissues. Humans typically absorb half their creatine through their diet, with synthesis providing the remainder. Loss of creatine synthesis appears to affect the brain disproportionately because the blood-brain barrier limits access of dietary creatine to the central nervous system. High levels of guanidinoacetate in the brain probably affect GABA-ergic pathways and also have an epileptogenic effect. 5 6 In the absence of enzyme replacement therapy, the current treatment options include oral creatine supplementation to replace endogenously synthesised creatine, and dietary manipulation combining supplementation of ornithine with restriction of arginine, to reduce guanidinoacetate toxicity.
Creatine supplementation is the easier option; highdose creatine is offered as a powder that can be given with food. Despite the blood-brain barrier restricting creatine transport into the central nervous system, high-dose creatine therapy significantly increases brain creatine concentrations.
2 Dietary arginine restriction (a low-protein diet), with ornithine supplementation is more complex, but has been used with some success as a second-line therapy. If metabolic treatment is offered from birth or early childhood, it may prevent features of the condition from developing. 7 There is still limited evidence as most cases have been diagnosed later in childhood or in adulthood, but there are reports of children with early diagnosis and treatment who have normal cognition. Once there is brain damage, correcting the metabolic imbalance may not improve cognition, but can dramatically reduce seizure frequency which improves quality of life and may reduce mortality. 6 
Outcome
He was started on oral creatine which was increased gradually to a dose of 24 g daily in divided doses. A 3-day diet diary showed that dietary protein intake was not excessive (<1 g/kg) and due to his learning difficulties and behavioural problems, we felt that significant alterations in diet were not appropriate.
Nine months after starting creatine, he has been seizure free for 4 months. He is more alert and affectionate. There has also been some challenging behaviour, possibly linked to increased alertness. Reported side effects have included an increased appetite, initial weight gain (now stable) and increased urinary frequency.
Blood and urine tests showed a significant improvement (table 2) .
Conclusion
GAMT deficiency is a rare cause of epilepsy and learning difficulties with an effective treatment. The clue to the diagnosis may come from a routine blood test of renal function, and can be confirmed using blood and urine samples, genetic testing or MR spectroscopy. Early treatment appears to affect prognosis; rather like Wilson's disease, this is a diagnosis not to miss. Treatment as an adult can dramatically reduce seizure frequency, in turn affecting quality of life, morbidity and mortality. 
